UNSPSC 51271626: Cinchocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C20H29N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z97702A5DG, chemically known as 4-quinolinecarboxamide, 2-butoxy-n-(2-(diethylamino)ethyl)- but more generally known as cinchocaine hydrochloride, which bears US NIH Compound Identifier 3025. European Medicines Agency schedules Cinchocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01302MIG.

Most nations, for tariff and trade purposes, schedule cinchocaine hydrochloride under HS 29334910. SMILES: CCCCOC1CC(C2CCCCC2N1)C(=O)NCCN(CC)CC.CL.

UNSPSC 51271626 Cinchocaine hydrochloride is a Commodity code covering a local anesthetic pharmaceutical ingredient that state and local governments procure through cooperative purchasing agreements and multi-source generic pharmaceutical contracts. The recent solicitation activity shows that this code supports state purchasing cooperative procurement of generic pharmaceuticals and over-the-counter products distributed to government healthcare facilities, correctional institutions, and other state and local health programs. Issuing bodies under this code include state purchasing cooperatives administering multi-state purchasing alliances, which consolidate demand across multiple participating states and local government entities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity and structures contracts to reach participating members across multiple jurisdictions.

MMCAP's RFP S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026 with a response deadline of March 26, 2026, represents the most recent relevant opportunity. The procurement establishes multiple contracts for generic pharmaceuticals including cinchocaine hydrochloride and similar injectable local anesthetics, with products required to be available in the marketplace by May 15, 2026 and contracts effective July 1, 2026. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and offer pricing flexibility through flat price, net price, or WAC-minus structures. The contract carries a two-year initial term with optional extensions, administrative fees of 3 percent on all purchases, and performance penalties ranging from $200 to $1,500 per violation. Evaluation weighs price competitiveness at 75 percent, with the remaining 25 percent split among fixed pricing, administrative compliance, EDI capability, and administrative fee agreement. Participating states include Minnesota and Oregon with broader multi-state reach through MMCAP members.